E-LIB Suche - Ergebnisse für: Salar, A.

1

Comparison Between aaIPI, LAB‐PI, NCCN‐IPI and GELTAMO‐IPI ..:

Martin‐Moro, F. ; Marquet‐Palomanes, J. ; Bento, L....
Hematological Oncology. 41 (2023) S2 - p. 413-414 , 2023

Link: https://doi.org/10.1002/..

2

A phase II, open‐label, multicenter study of capivasertib, ..:

Hodson, D. ; Shouse, G. ; Shin, H....
Hematological Oncology. 41 (2023) S2 - p. 562-564 , 2023

Link: https://doi.org/10.1002/..

3

Bone Marrow Assessment may be Omitted in Newly Diagnosed Di..:

Martin‐Moro, F. ; Lopez‐Pereira, P. ; Marquet‐Palomanes, J....
Hematological Oncology. 41 (2023) S2 - p. 403-404 , 2023

Link: https://doi.org/10.1002/..

4

MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VE..:

Sehn, L. ; Sarkozy, C. ; Song, Y....
Hematological Oncology. 41 (2023) S2 - p. 168-170 , 2023

Link: https://doi.org/10.1002/..

5

Genetic characterization in tissue and cfDNA in marginal zo..:

Diez‐Feijóo, R. ; Lafuente, M. ; Garcia‐Gisbert, N....
Hematological Oncology. 41 (2023) S2 - p. 323-324 , 2023

Link: https://doi.org/10.1002/..

6

GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY..:

Dickinson, M. ; Carlo‐Stella, C. ; Morschhauser, F....
Hematological Oncology. 41 (2023) S2 - p. 144-146 , 2023

Link: https://doi.org/10.1002/..

7

IMPACT OF TUMOR MUTATIONAL BURDEN ON THE RESPONSE TO IMMUNO..:

Lafuente, M. ; Diez‐Feijóo, R. ; Fernández‐Rodríguez, C....
Hematological Oncology. 41 (2023) S2 - p. 643-644 , 2023

Link: https://doi.org/10.1002/..

8

Lenalidomide in combination with R‐ESHAP in patients with r..:

Martín García‐Sancho, A. ; Baile, M. ; Rodríguez, G....
British Journal of Haematology. 203 (2023) 2 - p. 202-211 , 2023

Link: https://doi.org/10.1111/..

9

P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PAT..:

Zinzani, P. L. ; Özcan, M. ; Sapunarova, K....
HemaSphere. 6 (2022) - p. 1028-1029 , 2022

Link: https://doi.org/10.1097/..

10

P1137: ACCURACY AND PROGNOSTIC IMPACT OF FDG PET/CT AND BIO..:

Ródenas Quiñonero, I. ; Chen-Liang, T. ; Martín-Santos, T....
HemaSphere. 6 (2022) - p. 1027-1028 , 2022

Link: https://doi.org/10.1097/..

11

PB2083: STUDY CONDUCT AND PATIENT SAFETY DURING THE COVID-1..:

Canales, M. A. ; Buchholz, T. A. ; Ishikawa, T....
HemaSphere. 6 (2022) - p. 1954-1955 , 2022

Link: https://doi.org/10.1097/..

12

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDO..:

Sehn, L. H. ; Hübel, K. ; Luminari, S....
HemaSphere. 6 (2022) - p. 993-994 , 2022

Link: https://doi.org/10.1097/..

13

INMIND: A PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND R..:

Hübel, K. ; Scholz, C. W. ; Luminari, S....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

14

CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH DIFFUSE LAR..:

Franch‐Sarto, M. ; Garcia‐Calduch, O. ; Rivas, A....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

15

A GENE SIGNATURE TO PREDICT RISK OF TRANSFORMATION IN PATIE..:

Fernandez‐Miranda, I. ; Dominguez, M. ; Pedrosa, L....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..